If granted, the test’s approval process could be accelerated. The submission comes after two clinical studies conducted on the test showed consistently positive results, according to a July 9 news release from Mainz.
The test combines a traditional fecal immunochemical test with special biomarkers, alongside artificial intelligence and machine-learning algorithms.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
